Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson's Disease

BARCELONA, Spain, March 17, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today shared proof-of-concept data from its Chronos-PD program, demonstrating that biological changes in individuals with Parkinson's disease (PD) occur more than a decade before clinical diagnosis, with potential future implications for early detection and intervention.